Pacer Advisors Inc. Boosts Stake in Haemonetics Corporation $HAE

Pacer Advisors Inc. raised its stake in shares of Haemonetics Corporation (NYSE:HAE) by 3,597.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 207,121 shares of the medical instruments supplier’s stock after buying an additional 201,519 shares during the quarter. Pacer Advisors Inc.’s holdings in Haemonetics were worth $11,673,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. AQR Capital Management LLC boosted its stake in shares of Haemonetics by 48.6% during the fourth quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier’s stock valued at $253,523,000 after acquiring an additional 1,034,226 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Haemonetics by 994.7% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock valued at $110,615,000 after purchasing an additional 1,254,035 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Haemonetics by 21.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock valued at $74,731,000 after purchasing an additional 233,119 shares in the last quarter. North Peak Capital Management LLC boosted its stake in shares of Haemonetics by 204.4% during the 4th quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock worth $88,405,000 after purchasing an additional 740,626 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH boosted its stake in shares of Haemonetics by 17.3% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 841,017 shares of the medical instruments supplier’s stock worth $47,400,000 after purchasing an additional 124,020 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Stock Down 1.6%

HAE opened at $85.37 on Wednesday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The stock has a market capitalization of $3.88 billion, a price-to-earnings ratio of 42.26, a price-to-earnings-growth ratio of 1.75 and a beta of 0.52. The business has a 50-day moving average of $75.90 and a two-hundred day moving average of $66.21. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $88.58.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. During the same period in the prior year, the firm posted $1.24 EPS. The company’s revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, research analysts expect that Haemonetics Corporation will post 5.21 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Mizuho boosted their price objective on shares of Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, June 25th. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $72.00 to $80.00 in a research report on Friday, May 22nd. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, May 23rd. Finally, BTIG Research reiterated a “buy” rating and issued a $84.00 price target on shares of Haemonetics in a report on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $78.89.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.